Merck Stock: Still Discounted To Graham P/E

kemalbas/iStock via Getty ImagesMRK stock: Still a Buy We last covered Merck (NYSE:MRK) back in July 2022 with a bullish thesis (as you can see from the chart below). At that time, the stock was trading around $75 per share at about 12.5x FWD P/E. And the bullish thesis was pretty obvious to us (with our key points quoted below). Merck, currently priced at about 12.5x FW P/E, is still undervalued by a sizable margin. Growth from pipeline drugs and especially Molnupiravir is not properly priced in, leadi ...